164 related articles for article (PubMed ID: 16844208)
1. Neuroprotective effects of caffeine in the model of 6-hydroxydopamine lesion in rats.
Aguiar LM; Nobre HV; Macêdo DS; Oliveira AA; Freitas RM; Vasconcelos SM; Cunha GM; Sousa FC; Viana GS
Pharmacol Biochem Behav; 2006 Jul; 84(3):415-9. PubMed ID: 16844208
[TBL] [Abstract][Full Text] [Related]
2. CSC, an adenosine A(2A) receptor antagonist and MAO B inhibitor, reverses behavior, monoamine neurotransmission, and amino acid alterations in the 6-OHDA-lesioned rats.
Aguiar LM; Macêdo DS; Vasconcelos SM; Oliveira AA; de Sousa FC; Viana GS
Brain Res; 2008 Jan; 1191():192-9. PubMed ID: 18164694
[TBL] [Abstract][Full Text] [Related]
3. Caffeine neuroprotective effects on 6-OHDA-lesioned rats are mediated by several factors, including pro-inflammatory cytokines and histone deacetylase inhibitions.
Machado-Filho JA; Correia AO; Montenegro AB; Nobre ME; Cerqueira GS; Neves KR; Naffah-Mazzacoratti Mda G; Cavalheiro EA; de Castro Brito GA; de Barros Viana GS
Behav Brain Res; 2014 May; 264():116-25. PubMed ID: 24525422
[TBL] [Abstract][Full Text] [Related]
4. Nicotine alters striatal glutamate function and decreases the apomorphine-induced contralateral rotations in 6-OHDA-lesioned rats.
Meshul CK; Kamel D; Moore C; Kay TS; Krentz L
Exp Neurol; 2002 May; 175(1):257-74. PubMed ID: 12009777
[TBL] [Abstract][Full Text] [Related]
5. Neuroprotective and neurotrophic effect of apomorphine in the striatal 6-OHDA-lesion rat model of Parkinson's disease.
Yuan H; Sarre S; Ebinger G; Michotte Y
Brain Res; 2004 Nov; 1026(1):95-107. PubMed ID: 15476701
[TBL] [Abstract][Full Text] [Related]
6. Caffeine and CSC, adenosine A2A antagonists, offer neuroprotection against 6-OHDA-induced neurotoxicity in rat mesencephalic cells.
Nobre HV; Cunha GM; de Vasconcelos LM; Magalhães HI; Oliveira Neto RN; Maia FD; de Moraes MO; Leal LK; Viana GS
Neurochem Int; 2010 Jan; 56(1):51-8. PubMed ID: 19782116
[TBL] [Abstract][Full Text] [Related]
7. Increased progenitor cell proliferation and astrogenesis in the partial progressive 6-hydroxydopamine model of Parkinson's disease.
Aponso PM; Faull RL; Connor B
Neuroscience; 2008 Feb; 151(4):1142-53. PubMed ID: 18201835
[TBL] [Abstract][Full Text] [Related]
8. Chronic, systemic treatment with a metabotropic glutamate receptor 5 antagonist produces anxiolytic-like effects and reverses abnormal firing activity of projection neurons in the basolateral nucleus of the amygdala in rats with bilateral 6-OHDA lesions.
Chen L; Liu J; Ali U; Gui ZH; Hou C; Fan LL; Wang Y; Wang T
Brain Res Bull; 2011 Feb; 84(3):215-23. PubMed ID: 21255635
[TBL] [Abstract][Full Text] [Related]
9. In vivo extracellular recording of striatal neurons in the awake rat following unilateral 6-hydroxydopamine lesions.
Chen MT; Morales M; Woodward DJ; Hoffer BJ; Janak PH
Exp Neurol; 2001 Sep; 171(1):72-83. PubMed ID: 11520122
[TBL] [Abstract][Full Text] [Related]
10. Involvement of brain endogenous histamine in the degeneration of dopaminergic neurons in 6-hydroxydopamine-lesioned rats.
Liu CQ; Chen Z; Liu FX; Hu DN; Luo JH
Neuropharmacology; 2007 Dec; 53(7):832-41. PubMed ID: 17919665
[TBL] [Abstract][Full Text] [Related]
11. Failure of FK506 (tacrolimus) to alleviate apomorphine-induced circling in rat Parkinson model in spite of some cytoprotective effects in SH-SY5Y dopaminergic cells.
Manáková S; Singh A; Kääriäinen T; Taari H; Kulkarni SK; Männistö PT
Brain Res; 2005 Mar; 1038(1):83-91. PubMed ID: 15748876
[TBL] [Abstract][Full Text] [Related]
12. Neuroprotective effects of novel phosphatidylglycerol-based phospholipids in the 6-hydroxydopamine model of Parkinson's disease.
Crotty S; Fitzgerald P; Tuohy E; Harris DM; Fisher A; Mandel A; Bolton AE; Sullivan AM; Nolan Y
Eur J Neurosci; 2008 Jan; 27(2):294-300. PubMed ID: 18190522
[TBL] [Abstract][Full Text] [Related]
13. Serotonergic activation after 2-week intrastriatal infusion of L-dopa and slow recovery of circling in rats with unilateral nigral lesions.
Kääriäinen TM; García-Horsman JA; Piltonen M; Huotari M; Männistö PT
Basic Clin Pharmacol Toxicol; 2008 Mar; 102(3):300-7. PubMed ID: 17973898
[TBL] [Abstract][Full Text] [Related]
14. Protective effects of N-acetylserotonin against 6-hydroxydopamine-induced neurotoxicity.
Aguiar LM; Macedo DS; de Freitas RM; de Albuquerque Oliveira A; Vasconcelos SM; de Sousa FC; de Barros Viana GS
Life Sci; 2005 Mar; 76(19):2193-202. PubMed ID: 15733934
[TBL] [Abstract][Full Text] [Related]
15. Overexpression of D2/D3 receptors increases efficacy of ropinirole in chronically 6-OHDA-lesioned Parkinsonian rats.
Matsukawa N; Maki M; Yasuhara T; Hara K; Yu G; Xu L; Kim KM; Morgan JC; Sethi KD; Borlongan CV
Brain Res; 2007 Jul; 1160():113-23. PubMed ID: 17573046
[TBL] [Abstract][Full Text] [Related]
16. The corticotrophin-releasing factor-like peptide urocortin reverses key deficits in two rodent models of Parkinson's disease.
Abuirmeileh A; Lever R; Kingsbury AE; Lees AJ; Locke IC; Knight RA; Chowdrey HS; Biggs CS; Whitton PS
Eur J Neurosci; 2007 Jul; 26(2):417-23. PubMed ID: 17650114
[TBL] [Abstract][Full Text] [Related]
17. 1,25-Dihydroxyvitamin D3 administration to 6-hydroxydopamine-lesioned rats increases glial cell line-derived neurotrophic factor and partially restores tyrosine hydroxylase expression in substantia nigra and striatum.
Sanchez B; Relova JL; Gallego R; Ben-Batalla I; Perez-Fernandez R
J Neurosci Res; 2009 Feb; 87(3):723-32. PubMed ID: 18816795
[TBL] [Abstract][Full Text] [Related]
18. Lesion of subthalamic or motor thalamic nucleus in 6-hydroxydopamine-treated rats: effects on striatal glutamate and apomorphine-induced contralateral rotations.
Touchon JC; Moore C; Frederickson J; Meshul CK
Synapse; 2004 Mar; 51(4):287-98. PubMed ID: 14696016
[TBL] [Abstract][Full Text] [Related]
19. [Glia conditioned medium offers protection against the toxicity induced by 6-OH-dopamine in vivo].
Rojo A; Mena-Gómez MA; Blázquez A; Casarejos MJ; Fontán-Barreiro A; de Yébenes JG
Rev Neurol; 2002 Jun 16-30; 34(12):1112-8. PubMed ID: 12134273
[TBL] [Abstract][Full Text] [Related]
20. Modulation of the motor response to dopaminergic drugs in a parkinsonian model of combined dopaminergic and noradrenergic degeneration.
Pérez V; Sosti V; Rubio A; Barbanoj M; Rodríguez-Alvarez J; Kulisevsky J
Eur J Pharmacol; 2007 Dec; 576(1-3):83-90. PubMed ID: 17888901
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
